WEBVTT - The First Pig to Human Kidney Transplant

0:00:15.356 --> 0:00:24.076
<v Speaker 1>Pushkin. Rick Slayman is sixty two years old, lives in

0:00:24.116 --> 0:00:28.116
<v Speaker 1>a suburb of Boston, works for the state Department of Transportation,

0:00:29.036 --> 0:00:32.436
<v Speaker 1>and about five years ago he got a kidney transplant.

0:00:33.436 --> 0:00:37.996
<v Speaker 1>Then last year his new kidney stopped working, his health declined.

0:00:38.436 --> 0:00:42.956
<v Speaker 1>His prognosis was pretty bad, so earlier this year, he

0:00:42.996 --> 0:00:46.116
<v Speaker 1>and his doctors decided that he would be the first

0:00:46.156 --> 0:00:48.676
<v Speaker 1>person in the history of the world to get a

0:00:48.756 --> 0:00:54.196
<v Speaker 1>kidney transplant from a genetically engineered pig. Surgeons did the

0:00:54.196 --> 0:00:58.836
<v Speaker 1>transplant on March sixteenth, and two weeks later, Rix s

0:00:58.916 --> 0:01:02.276
<v Speaker 1>Layman walked out of the hospital. It's still too soon

0:01:02.316 --> 0:01:04.796
<v Speaker 1>to say how he'll do in the coming months, but

0:01:05.316 --> 0:01:14.476
<v Speaker 1>as of this recording, he's doing well. I'm Jacob Boltstein

0:01:14.556 --> 0:01:16.756
<v Speaker 1>and this is What's Your Problem, the show where I

0:01:16.836 --> 0:01:20.276
<v Speaker 1>talk to people who are trying to make technological progress.

0:01:20.716 --> 0:01:25.276
<v Speaker 1>My guest today is Mike Curtis. He's the CEO of Egenesis,

0:01:25.556 --> 0:01:29.716
<v Speaker 1>the company that bred the genetically engineered pig that provided

0:01:29.716 --> 0:01:33.956
<v Speaker 1>the kidney for Rick Slicker. Every year, thousands of people

0:01:34.156 --> 0:01:37.436
<v Speaker 1>die waiting for an organ transplant that never comes. And

0:01:37.716 --> 0:01:42.676
<v Speaker 1>so Mike's problem is this, is it possible to genetically

0:01:42.756 --> 0:01:48.996
<v Speaker 1>engineer pigs to provide organs, kidneys, livers, hearts for people,

0:01:49.756 --> 0:01:52.236
<v Speaker 1>and in the long run, is it possible to make

0:01:52.356 --> 0:01:56.596
<v Speaker 1>pig organs that work even better than human organs for

0:01:56.876 --> 0:02:03.996
<v Speaker 1>human transplant patients. So for a really long time, right,

0:02:04.076 --> 0:02:07.716
<v Speaker 1>like hundreds of years, people have had this idea of

0:02:07.836 --> 0:02:14.396
<v Speaker 1>transplanting organs or skin from animals to people, like where

0:02:14.436 --> 0:02:17.076
<v Speaker 1>do you where do you date the beginning of this

0:02:17.196 --> 0:02:17.676
<v Speaker 1>idea too?

0:02:18.356 --> 0:02:21.396
<v Speaker 2>It was it was even pre dated human human transplants.

0:02:21.436 --> 0:02:24.476
<v Speaker 2>So as soon as you know, physicians realize that organs

0:02:24.476 --> 0:02:27.356
<v Speaker 2>can fail, I think the first instinct was can we

0:02:27.396 --> 0:02:30.036
<v Speaker 2>get them from somewhere else? Right? And in the early

0:02:30.116 --> 0:02:33.996
<v Speaker 2>days of that horribly right, no, no good success. So

0:02:34.156 --> 0:02:36.076
<v Speaker 2>we kind of pre you know, date that to the

0:02:36.316 --> 0:02:38.836
<v Speaker 2>dawn of modern medicine. And nothing worked.

0:02:39.036 --> 0:02:43.196
<v Speaker 1>And nothing worked because basically the human immune system rejected

0:02:43.316 --> 0:02:44.076
<v Speaker 1>the transplants.

0:02:44.236 --> 0:02:45.676
<v Speaker 2>And that was before we even knew what that was.

0:02:45.716 --> 0:02:49.556
<v Speaker 3>But right, yeah, And so to jump forward a very

0:02:49.596 --> 0:02:55.116
<v Speaker 3>long way, it seems like Crisper, this ability to edit

0:02:55.556 --> 0:02:58.036
<v Speaker 3>genes is sort of a key breakthrough.

0:02:58.516 --> 0:03:01.276
<v Speaker 1>Is that the kind of key moment that enables this

0:03:01.356 --> 0:03:04.196
<v Speaker 1>new era that seems to be beginning right now?

0:03:04.436 --> 0:03:08.956
<v Speaker 2>Absolutely. There were some challenges in the cross species transplant

0:03:08.956 --> 0:03:12.276
<v Speaker 2>that just unresolvable until the discovery of Crisper. So the

0:03:12.276 --> 0:03:15.116
<v Speaker 2>one that we took on was in the nineties, it

0:03:15.156 --> 0:03:20.316
<v Speaker 2>was discovered that poresign retroviruses that are indigenous in the genome,

0:03:20.356 --> 0:03:23.076
<v Speaker 2>so they're kind of embedded in the pig genome, could

0:03:23.076 --> 0:03:25.316
<v Speaker 2>infect human cells. And in the nineties, you know, we

0:03:25.316 --> 0:03:29.236
<v Speaker 2>were coming out of the HIV epidemic, and we did

0:03:29.236 --> 0:03:31.956
<v Speaker 2>not want to, you know, cause another problem. So we

0:03:31.956 --> 0:03:34.996
<v Speaker 2>didn't want to have a cross species zoonotic event. So

0:03:35.276 --> 0:03:37.476
<v Speaker 2>in many countries around the world they put a moratorium

0:03:37.636 --> 0:03:42.676
<v Speaker 2>on cross species transplantation because of this risk of indigenous retroviruses.

0:03:42.756 --> 0:03:46.556
<v Speaker 1>And so I just want to pause here because I

0:03:46.596 --> 0:03:50.636
<v Speaker 1>didn't know about indogenous retroviruses until I started preparing for

0:03:50.676 --> 0:03:54.436
<v Speaker 1>this interview, and it totally blew my mind that there

0:03:54.516 --> 0:03:58.836
<v Speaker 1>is such a thing. Right, So, an indogenous retrovirus, as

0:03:58.876 --> 0:03:59.916
<v Speaker 1>I understand.

0:03:59.556 --> 0:04:00.436
<v Speaker 2>It is.

0:04:02.036 --> 0:04:05.396
<v Speaker 1>Not like a disease that a that an animal has

0:04:05.396 --> 0:04:08.556
<v Speaker 1>in this case, a poor sign. Indogenous retrovirus obviously is

0:04:08.556 --> 0:04:11.516
<v Speaker 1>an indogen retrovirus in a pig, and it doesn't mean

0:04:11.516 --> 0:04:13.436
<v Speaker 1>that the pig is sick It means that in the

0:04:13.516 --> 0:04:17.436
<v Speaker 1>genome of every pig there is genetic code to code

0:04:17.476 --> 0:04:22.116
<v Speaker 1>in that pig a retrovirus, right, And similarly, in humans

0:04:22.156 --> 0:04:25.796
<v Speaker 1>there are other indogenous retroviruses. We have in our genome

0:04:26.196 --> 0:04:32.476
<v Speaker 1>the code for retroviruses, that's right. Why why do mammals

0:04:32.516 --> 0:04:35.236
<v Speaker 1>have the code for viruses in our genomes?

0:04:35.316 --> 0:04:38.396
<v Speaker 2>Yeah? What's interesting because there are some functions that are

0:04:38.476 --> 0:04:42.596
<v Speaker 2>ascribed to these indigenous retroviruses. So they kind of co evolved,

0:04:42.956 --> 0:04:45.836
<v Speaker 2>you know, with pigs with people, and they pick up

0:04:45.836 --> 0:04:49.596
<v Speaker 2>some function, right, And so we don't completely understand why

0:04:49.596 --> 0:04:54.516
<v Speaker 2>they're there, but they're there and they pose a risk, right,

0:04:54.836 --> 0:04:59.196
<v Speaker 2>an infectious disease risk to patients, especially when you think

0:04:59.196 --> 0:05:01.756
<v Speaker 2>about patients who might be under immino suppression.

0:05:02.036 --> 0:05:04.036
<v Speaker 1>And so, just to be clear, just I won't I

0:05:04.036 --> 0:05:05.796
<v Speaker 1>don't want to be labor this, but it is really

0:05:05.836 --> 0:05:11.356
<v Speaker 1>extraordinary coming to it new. The notion is a very

0:05:11.476 --> 0:05:15.276
<v Speaker 1>very very long time ago, some pig in this case

0:05:15.316 --> 0:05:19.436
<v Speaker 1>got infected with a virus and that virus made its

0:05:19.476 --> 0:05:22.916
<v Speaker 1>way into the genome of essentially all the pigs living today,

0:05:24.316 --> 0:05:29.956
<v Speaker 1>and that genetic code is not harmful to pigs, but

0:05:30.076 --> 0:05:33.556
<v Speaker 1>there is a fear that if you took a pig kidney, say,

0:05:33.556 --> 0:05:35.756
<v Speaker 1>and put it in a human being, the code for

0:05:35.836 --> 0:05:38.356
<v Speaker 1>that virus, which is fine in pigs, might be harmful

0:05:38.356 --> 0:05:38.796
<v Speaker 1>in people.

0:05:39.116 --> 0:05:42.356
<v Speaker 2>Exactly. It's an unknown risk, ye.

0:05:42.796 --> 0:05:46.556
<v Speaker 1>And so in the nineties, particularly as you said, in

0:05:46.596 --> 0:05:48.836
<v Speaker 1>the context of the fear of HIV, people are thinking

0:05:48.876 --> 0:05:52.836
<v Speaker 1>about doing could we transplant a pig kidney into a

0:05:52.916 --> 0:05:57.476
<v Speaker 1>human and regulators essentially are saying, well, one reason you

0:05:57.516 --> 0:06:01.236
<v Speaker 1>cannot do it is because of these endogenous retroviruses in

0:06:01.276 --> 0:06:02.436
<v Speaker 1>the pigs DNA.

0:06:02.596 --> 0:06:05.676
<v Speaker 2>Exactly, and we can't quantify the risk, and so we

0:06:05.716 --> 0:06:08.756
<v Speaker 2>don't know what will happen, and we actually don't want

0:06:08.796 --> 0:06:10.676
<v Speaker 2>to know. You need to come up with a way

0:06:10.676 --> 0:06:14.436
<v Speaker 2>to mitigate the risk of retroviral transmission from the donor

0:06:14.476 --> 0:06:15.756
<v Speaker 2>to the recipient.

0:06:15.396 --> 0:06:19.556
<v Speaker 1>Okay, And so that's just like a red light, do

0:06:19.716 --> 0:06:23.156
<v Speaker 1>not pass. Go stop doing this for a while. Once

0:06:23.196 --> 0:06:23.676
<v Speaker 1>that happens.

0:06:23.716 --> 0:06:27.396
<v Speaker 2>In the nineties, exactly, most of the people that were

0:06:27.436 --> 0:06:29.556
<v Speaker 2>investing in the space stopped investing in the space. The

0:06:29.596 --> 0:06:32.836
<v Speaker 2>progression towards clinic stopped. It really slowed the whole field

0:06:32.836 --> 0:06:34.796
<v Speaker 2>down because no one knew exactly how to quantify the

0:06:34.876 --> 0:06:37.156
<v Speaker 2>risk or then what to do about it. And so

0:06:37.236 --> 0:06:40.636
<v Speaker 2>any pig genome you'll have between fifty and seventy copies

0:06:41.076 --> 0:06:44.316
<v Speaker 2>of the retrovirus scattered throughout the genome. And so even

0:06:44.356 --> 0:06:46.956
<v Speaker 2>if you wanted to go in and remove them, there

0:06:47.036 --> 0:06:49.356
<v Speaker 2>was no technology available that would allow you to do that.

0:06:50.596 --> 0:06:53.316
<v Speaker 2>And no one knew of a way to actually actively

0:06:53.356 --> 0:06:56.196
<v Speaker 2>get rid of these viruses right until the discovery of Crisper.

0:06:56.836 --> 0:07:01.596
<v Speaker 1>So Crisper comes along what ten issuars twelve years ago,

0:07:01.956 --> 0:07:07.636
<v Speaker 1>and it's this incredible technology for editing a genome. Right,

0:07:10.636 --> 0:07:14.996
<v Speaker 1>people think, oh, maybe we could solve that poresine and

0:07:15.116 --> 0:07:17.636
<v Speaker 1>dogenous retrovirus problem using Crisper.

0:07:18.036 --> 0:07:19.996
<v Speaker 2>Yeah, so this is what George Church kind of took

0:07:20.036 --> 0:07:22.396
<v Speaker 2>up at Harvard was like, it kind of what would

0:07:22.356 --> 0:07:24.436
<v Speaker 2>do we use chrispher for? And this this problem was

0:07:24.476 --> 0:07:26.436
<v Speaker 2>out there and George took it on and said, well,

0:07:26.476 --> 0:07:29.156
<v Speaker 2>let's see if you can inactivate all copies of the

0:07:29.156 --> 0:07:31.876
<v Speaker 2>retroviruses in the pig geno. The beautiful part about Crisper

0:07:32.556 --> 0:07:35.076
<v Speaker 2>is once you give it a sequence, right, it will

0:07:35.156 --> 0:07:38.636
<v Speaker 2>edit all copies of that sequence in a given genome. Now,

0:07:38.676 --> 0:07:43.036
<v Speaker 2>the worry was that you would then create basically Swiss

0:07:43.076 --> 0:07:45.156
<v Speaker 2>cheese out of the genome. Right, you would create an

0:07:45.236 --> 0:07:48.076
<v Speaker 2>unviable genome. There's too many edits, was the original thought.

0:07:48.476 --> 0:07:50.756
<v Speaker 2>But George and the team at Harvard showed that no,

0:07:50.836 --> 0:07:54.516
<v Speaker 2>you could actually inactivate all copies of the retrovirus and

0:07:54.596 --> 0:07:56.596
<v Speaker 2>then produce a viable pig.

0:07:57.156 --> 0:07:59.196
<v Speaker 1>Right, because I suppose the other question is like, even

0:07:59.236 --> 0:08:03.796
<v Speaker 1>if you can cleanly make all the edits, do does

0:08:03.836 --> 0:08:07.676
<v Speaker 1>the pig actually need this indogenous retrovirus for a reason

0:08:07.716 --> 0:08:08.996
<v Speaker 1>we don't understand.

0:08:08.636 --> 0:08:10.516
<v Speaker 2>Right, And we know it does if you if you

0:08:10.556 --> 0:08:12.516
<v Speaker 2>completely knock it out or get rid of it, the

0:08:12.516 --> 0:08:16.156
<v Speaker 2>pigs are not healthy. So we make a relatively subtle

0:08:16.236 --> 0:08:19.716
<v Speaker 2>change to the viral genome that that prevents the virus

0:08:19.716 --> 0:08:22.636
<v Speaker 2>from replicating. So with this edit, the virus can no

0:08:22.676 --> 0:08:24.156
<v Speaker 2>longer replicate hot.

0:08:24.196 --> 0:08:27.676
<v Speaker 1>But so you don't knock it. You don't entirely remove

0:08:27.756 --> 0:08:29.036
<v Speaker 1>the sequence from the genome.

0:08:29.116 --> 0:08:29.716
<v Speaker 2>You just.

0:08:31.356 --> 0:08:35.156
<v Speaker 1>Edit the genome such that this virus, once it's expressed,

0:08:35.516 --> 0:08:36.396
<v Speaker 1>cannot replicate.

0:08:36.596 --> 0:08:39.436
<v Speaker 2>Right, So essentially inactivate those of Dodges viruses.

0:08:39.756 --> 0:08:42.116
<v Speaker 1>And so this idea from George Churchill was one of

0:08:42.156 --> 0:08:46.396
<v Speaker 1>the like giant names in genetics. Right famous scientists was

0:08:46.476 --> 0:08:49.196
<v Speaker 1>that the origin of the company.

0:08:49.356 --> 0:08:53.076
<v Speaker 2>So it came from from from George's lab and we

0:08:53.076 --> 0:08:59.356
<v Speaker 2>we one of his postdocs started Egenesis by outlcensing the

0:08:59.396 --> 0:09:03.316
<v Speaker 2>technology from Harvard. So the original idea was to start

0:09:03.316 --> 0:09:07.956
<v Speaker 2>Egenesis with the idea of making animals that were retroviray

0:09:07.996 --> 0:09:11.876
<v Speaker 2>inactivated and then also do the rest of the editing

0:09:12.156 --> 0:09:15.276
<v Speaker 2>right that made the pigs more compatible with human recipient.

0:09:15.316 --> 0:09:17.396
<v Speaker 2>So that's how we got into the field. And then

0:09:17.516 --> 0:09:21.956
<v Speaker 2>from the from then we've built the additional editing to

0:09:21.996 --> 0:09:24.956
<v Speaker 2>provide organs that are more compatible with first non human

0:09:24.956 --> 0:09:26.436
<v Speaker 2>primates and then now with people.

0:09:26.796 --> 0:09:31.836
<v Speaker 1>So you have inactivated the endogenous retrovirus in the pig.

0:09:32.316 --> 0:09:35.996
<v Speaker 1>This is like step one, right, But at this point,

0:09:36.116 --> 0:09:41.116
<v Speaker 1>if you tried to take that kidney, even though you've

0:09:41.116 --> 0:09:45.236
<v Speaker 1>solved the retrovirus problem, it's still a pig kidney, right,

0:09:45.316 --> 0:09:47.516
<v Speaker 1>and the human body would know that and would not

0:09:48.196 --> 0:09:51.276
<v Speaker 1>accept it. So what do you have to do next?

0:09:51.436 --> 0:09:54.396
<v Speaker 2>Sure, and so if you just took an unedited pig

0:09:54.476 --> 0:09:55.916
<v Speaker 2>kidney and try to put it into a monkey or

0:09:55.956 --> 0:09:59.356
<v Speaker 2>to a person, to be rejected within minutes. And that's

0:09:59.396 --> 0:10:02.996
<v Speaker 2>primarily due to what we call hyperacute rejection, where the

0:10:03.116 --> 0:10:07.396
<v Speaker 2>humans are recognizing the carbohydrate differences between pigs and humans.

0:10:07.396 --> 0:10:12.676
<v Speaker 2>So carbohydrates are that coat all the cells, and humans

0:10:12.716 --> 0:10:16.236
<v Speaker 2>have antibodies that can recognize those pig sugars. So what

0:10:16.276 --> 0:10:19.996
<v Speaker 2>we do is we inactivate three genes responsible for those

0:10:20.036 --> 0:10:23.756
<v Speaker 2>carbohydrate differences between pigs and humans. Once you do that,

0:10:23.796 --> 0:10:25.716
<v Speaker 2>we create what we call the triple knockout. So we

0:10:25.836 --> 0:10:31.236
<v Speaker 2>inactivate those genes, knocking out those carbohydrate differences and eliminating

0:10:31.956 --> 0:10:32.916
<v Speaker 2>hypercute rejection.

0:10:34.156 --> 0:10:41.676
<v Speaker 1>And when you create a pig with those particular carbohydrates eliminated,

0:10:42.756 --> 0:10:45.596
<v Speaker 1>does it matter to the pig? Is the pig sicker?

0:10:45.636 --> 0:10:49.316
<v Speaker 2>As a result, we haven't seen any impact on the

0:10:49.636 --> 0:10:52.356
<v Speaker 2>health or longevity of a pig. So, for instance, we

0:10:52.436 --> 0:10:55.796
<v Speaker 2>have several animals in our colony that are a couple

0:10:55.836 --> 0:10:58.836
<v Speaker 2>of years old, and so we haven't seen any effects

0:10:58.876 --> 0:11:01.516
<v Speaker 2>on the longevity of those animals. So no, we haven't

0:11:01.516 --> 0:11:02.396
<v Speaker 2>seen any downside.

0:11:02.596 --> 0:11:07.316
<v Speaker 1>Okay, so you've inactivated the endogenous retrovirus and now you've

0:11:07.356 --> 0:11:12.236
<v Speaker 1>eliminated the carbo hydrates that are causing acute rejection. There's

0:11:12.316 --> 0:11:14.796
<v Speaker 1>like one more set of changes you've got to make, right,

0:11:14.836 --> 0:11:15.196
<v Speaker 1>That's right.

0:11:15.516 --> 0:11:17.636
<v Speaker 2>So what the field has shown over the past forty years.

0:11:17.676 --> 0:11:21.156
<v Speaker 2>Is that if you add human genes to the pig genome,

0:11:21.556 --> 0:11:25.036
<v Speaker 2>you can help regulate different areas of incompatibility. So when

0:11:25.076 --> 0:11:28.516
<v Speaker 2>we think about, for instance, coagulation, right, So the coagulation

0:11:28.636 --> 0:11:32.716
<v Speaker 2>factors in the pig are not one percent compatible with humans,

0:11:33.076 --> 0:11:36.356
<v Speaker 2>so we introduce human coagulation factors into the pig.

0:11:36.716 --> 0:11:39.356
<v Speaker 1>Coagulation factors just what causes the blood.

0:11:39.036 --> 0:11:42.276
<v Speaker 2>To clot basically or prevent the blood from clotting? Yeah,

0:11:42.316 --> 0:11:45.516
<v Speaker 2>either way, both both corrections, yep, absolutely. And then we

0:11:45.556 --> 0:11:49.356
<v Speaker 2>also add regulators of complement activation. The first kind of

0:11:49.396 --> 0:11:51.796
<v Speaker 2>immune response that you're going to get to a graft

0:11:52.236 --> 0:11:55.476
<v Speaker 2>in a transplant is what we call compliment activation, and

0:11:55.516 --> 0:11:58.316
<v Speaker 2>that leads to loss of cells, right, and that leads

0:11:58.356 --> 0:12:02.036
<v Speaker 2>to death of cells. But by introducing human complement regulators

0:12:02.276 --> 0:12:05.396
<v Speaker 2>into the poor scine tissue, we can slow down or

0:12:05.476 --> 0:12:09.436
<v Speaker 2>quiet that complement response. And then we add module later

0:12:09.636 --> 0:12:12.076
<v Speaker 2>of what we call the innate and adaptive immune response.

0:12:12.636 --> 0:12:16.076
<v Speaker 2>In total, we add in the animal that was used

0:12:16.116 --> 0:12:19.076
<v Speaker 2>in mister Slamon's transplant, we introduced a total of seven

0:12:19.676 --> 0:12:23.076
<v Speaker 2>regulatory human proteins. So if you add it together, it's

0:12:23.156 --> 0:12:27.716
<v Speaker 2>fifty nine edits to inactivate the retroviruses three edits to

0:12:27.796 --> 0:12:32.476
<v Speaker 2>improve the carbohydrate compatibility, and then seven edits to introduce

0:12:32.556 --> 0:12:35.356
<v Speaker 2>human regulatory trans genes, for a total of sixty nine edits.

0:12:35.476 --> 0:12:38.836
<v Speaker 1>So it's basically the first two categories are make it

0:12:38.916 --> 0:12:41.676
<v Speaker 1>less like a pig, and then the third category is

0:12:41.876 --> 0:12:43.116
<v Speaker 1>make it more like a person.

0:12:43.316 --> 0:12:44.796
<v Speaker 2>Yeah, that's a good way to think about it.

0:12:44.916 --> 0:12:49.516
<v Speaker 1>That's right, And I mean presumably at some margin you

0:12:49.636 --> 0:12:52.916
<v Speaker 1>want to make it as little like a pig and

0:12:53.076 --> 0:12:56.396
<v Speaker 1>as much like a person as possible. But the pig

0:12:56.436 --> 0:13:01.276
<v Speaker 1>still has to live, to grow up and have a kidney.

0:13:00.996 --> 0:13:05.636
<v Speaker 2>Right, absolutely, And we've produced animals with more trans genes

0:13:05.676 --> 0:13:08.916
<v Speaker 2>without any issue. But you can imagine at some point, right,

0:13:09.156 --> 0:13:11.076
<v Speaker 2>you'll reach a point where the pig no longer can

0:13:11.116 --> 0:13:14.516
<v Speaker 2>tolerate whatever the editing you're doing. We're actually already impressed

0:13:14.876 --> 0:13:17.596
<v Speaker 2>that we can produce healthy, viable pigs with this number

0:13:17.636 --> 0:13:20.876
<v Speaker 2>of edits. If you go back ten fifteen years, nobody

0:13:20.916 --> 0:13:24.956
<v Speaker 2>thought that you could viably do this. Even in activating

0:13:24.956 --> 0:13:27.476
<v Speaker 2>fifty nine copies of the retrovirus. Many felt that that

0:13:27.596 --> 0:13:29.636
<v Speaker 2>was too many and the genome wouldn't be able to

0:13:29.676 --> 0:13:32.196
<v Speaker 2>handle it. We can tell you that it's not easy,

0:13:32.236 --> 0:13:34.676
<v Speaker 2>and it's not trivial to do it. It took us

0:13:34.676 --> 0:13:36.916
<v Speaker 2>a lot of time to figure out how to do it,

0:13:37.436 --> 0:13:39.636
<v Speaker 2>but now we've shown it it is doable.

0:13:40.396 --> 0:13:42.916
<v Speaker 1>I'm sure that it's not easy, but I don't know

0:13:43.076 --> 0:13:48.396
<v Speaker 1>enough to understand, like what's hard about it? Like tell

0:13:48.436 --> 0:13:50.076
<v Speaker 1>me a thing that you had to figure out.

0:13:50.236 --> 0:13:53.396
<v Speaker 2>Sure, so when you do that much engineering to the genome,

0:13:53.436 --> 0:13:58.236
<v Speaker 2>you can get aberrations in the genome that prevents you

0:13:58.276 --> 0:14:00.276
<v Speaker 2>from making a pig. So one of the things that

0:14:00.316 --> 0:14:03.636
<v Speaker 2>we do is we do what's called clonal selection. So

0:14:03.756 --> 0:14:08.396
<v Speaker 2>we'll engineer thousands, tens of thousands of cells and then

0:14:08.516 --> 0:14:12.356
<v Speaker 2>select genomes based on viability. So, for instance, to so

0:14:12.476 --> 0:14:15.356
<v Speaker 2>produce our seventeen eighty four donor, we had to screen

0:14:15.436 --> 0:14:19.036
<v Speaker 2>over four thousand clones to find clones that had the

0:14:19.076 --> 0:14:21.796
<v Speaker 2>adequate quality of genome to then make pigs.

0:14:22.036 --> 0:14:25.076
<v Speaker 1>Huh. So let's just let's just talk about that for

0:14:25.076 --> 0:14:29.036
<v Speaker 1>a minute, like how that actually works, which is the

0:14:29.036 --> 0:14:32.916
<v Speaker 1>more basic question of just how does the whole thing work?

0:14:32.996 --> 0:14:35.556
<v Speaker 1>Like I get in a sort of abstracted space what

0:14:35.596 --> 0:14:40.396
<v Speaker 1>you're doing, but like in whatever in a you know,

0:14:40.436 --> 0:14:42.756
<v Speaker 1>in a cell, fundamentally there is a cell, right like,

0:14:42.756 --> 0:14:43.556
<v Speaker 1>what are we starting with.

0:14:43.756 --> 0:14:46.476
<v Speaker 2>So we'll take a sample of skin from an adult

0:14:46.796 --> 0:14:49.996
<v Speaker 2>what we call wild type so unedited pig. Then culture

0:14:50.036 --> 0:14:52.796
<v Speaker 2>those cells, make many cells, and then those are the

0:14:52.836 --> 0:14:54.476
<v Speaker 2>cells that we're going to edit. So those are the

0:14:54.516 --> 0:14:57.196
<v Speaker 2>cells that we take crisper. We make the fifty nine edits,

0:14:57.236 --> 0:14:59.156
<v Speaker 2>we make the triple knockout, and we make the seven

0:14:59.236 --> 0:15:02.996
<v Speaker 2>trans geens. In the case of the seventeen eighty four animal,

0:15:03.036 --> 0:15:05.356
<v Speaker 2>we did that through three sequential routes.

0:15:05.396 --> 0:15:07.636
<v Speaker 1>So just to be clear, the seventeen eighty four animal,

0:15:07.716 --> 0:15:10.436
<v Speaker 1>this is like one particular pig, the pig that donated

0:15:10.476 --> 0:15:12.396
<v Speaker 1>the kidney that is in a person right now.

0:15:12.476 --> 0:15:15.596
<v Speaker 2>So that's the seventeen eighty four refers to the genetics.

0:15:15.876 --> 0:15:19.516
<v Speaker 2>So we make many seventeen eighty four animals. So it's

0:15:19.556 --> 0:15:20.796
<v Speaker 2>a particular.

0:15:20.716 --> 0:15:23.236
<v Speaker 1>Edited genome, and it's the edited genome that you have

0:15:23.316 --> 0:15:23.956
<v Speaker 1>described to me.

0:15:24.036 --> 0:15:26.636
<v Speaker 2>Yeah, exactly, okay, right, So to make that animal, we

0:15:26.636 --> 0:15:29.156
<v Speaker 2>actually went through three rounds of editing, right, So we

0:15:29.196 --> 0:15:33.436
<v Speaker 2>would make the retroviolent activation make a pig, then take

0:15:33.476 --> 0:15:35.796
<v Speaker 2>those cells, edit them to make the try add the

0:15:35.836 --> 0:15:38.436
<v Speaker 2>truckle knockout, make a pig. Then we come back and

0:15:39.156 --> 0:15:40.476
<v Speaker 2>add the seven trans sheats.

0:15:40.276 --> 0:15:43.956
<v Speaker 1>So it's multiple generations. You're you are sort of adding

0:15:45.716 --> 0:15:49.276
<v Speaker 1>changes genetic mutations over successive generations.

0:15:49.516 --> 0:15:54.916
<v Speaker 2>Exactly why this allows us to select right. So there's

0:15:54.956 --> 0:15:59.676
<v Speaker 2>there's two there's there's two restrictions the time. Because we're

0:15:59.676 --> 0:16:02.116
<v Speaker 2>working with primary cells the time, you have to edit

0:16:02.156 --> 0:16:05.276
<v Speaker 2>them before they what we call sinat. So at some

0:16:05.316 --> 0:16:08.236
<v Speaker 2>point those cells stop dividing. You need to edit while

0:16:08.236 --> 0:16:10.636
<v Speaker 2>the cells are still divide, so you have a limited

0:16:10.756 --> 0:16:13.236
<v Speaker 2>number of days to do the editing, right, So we do.

0:16:13.516 --> 0:16:15.596
<v Speaker 2>So this is why we were doing three rounds of editing,

0:16:15.796 --> 0:16:18.676
<v Speaker 2>because we can get the retroviral in make a pig,

0:16:18.716 --> 0:16:20.356
<v Speaker 2>we can get the triple knockout make a pig. We

0:16:20.396 --> 0:16:22.476
<v Speaker 2>get the seven genes and make a pig. What's really

0:16:22.516 --> 0:16:25.036
<v Speaker 2>important to that whole process is at the end of

0:16:25.076 --> 0:16:31.596
<v Speaker 2>each editing round, we then screen individual cells for the genotype. Right,

0:16:31.636 --> 0:16:33.916
<v Speaker 2>And this is where we'll go through and screen you know,

0:16:34.276 --> 0:16:37.276
<v Speaker 2>up to four thousand cells to pick cells that look

0:16:37.716 --> 0:16:40.076
<v Speaker 2>like they have a good morphology and a good phenotype

0:16:40.196 --> 0:16:42.876
<v Speaker 2>for which we would then make a pig. So, once

0:16:42.876 --> 0:16:45.876
<v Speaker 2>we do the editing, we then pick individual cells that

0:16:45.916 --> 0:16:49.236
<v Speaker 2>we call clones, and then we grow those clones out,

0:16:49.396 --> 0:16:52.196
<v Speaker 2>and now we have an edited porsone genome, but we

0:16:52.196 --> 0:16:53.116
<v Speaker 2>still don't have a pig.

0:16:53.316 --> 0:16:56.556
<v Speaker 1>So you basically have a whatever, a petri dish full

0:16:56.556 --> 0:17:01.636
<v Speaker 1>of pig skin cells that have the genotype that you want, exactly, okay.

0:17:01.476 --> 0:17:02.836
<v Speaker 2>And so now we need to make a pig. And

0:17:02.996 --> 0:17:05.036
<v Speaker 2>the technology we use to turn a single cell into

0:17:05.076 --> 0:17:08.156
<v Speaker 2>a pig, it's called a somatic cell nuclear transfer. It

0:17:08.236 --> 0:17:10.716
<v Speaker 2>was similar to tchnology that was used to clone Dolly,

0:17:11.316 --> 0:17:13.996
<v Speaker 2>where we take the nucleus of the edited cell and

0:17:14.156 --> 0:17:18.236
<v Speaker 2>basically transfer it into the O site of a pig.

0:17:18.076 --> 0:17:21.476
<v Speaker 1>An egg cell. And and so this is now a

0:17:21.716 --> 0:17:24.996
<v Speaker 1>whatever thirty year old technology that they used to clone

0:17:24.996 --> 0:17:26.796
<v Speaker 1>a sheep with in the nineties exactly.

0:17:27.516 --> 0:17:30.116
<v Speaker 2>There's been some obviously improvements since then, but the core

0:17:30.276 --> 0:17:33.196
<v Speaker 2>idea is essentially the same. And then we use that

0:17:33.236 --> 0:17:36.116
<v Speaker 2>cloning technology to then make pigs. So we make an

0:17:36.116 --> 0:17:39.276
<v Speaker 2>embryo and then we transfer that embryo into a surrogate

0:17:39.356 --> 0:17:42.716
<v Speaker 2>sal and then that surrogate sal will carry the piglet

0:17:42.796 --> 0:17:43.396
<v Speaker 2>to term.

0:17:44.116 --> 0:17:47.116
<v Speaker 1>There's some ethical dimension to this, like like, what are

0:17:47.156 --> 0:17:48.796
<v Speaker 1>the relevant ethical dimensions to you?

0:17:49.116 --> 0:17:51.956
<v Speaker 2>Yeah, our focus is on preserving human health and saving

0:17:51.996 --> 0:17:54.916
<v Speaker 2>patients who are dying on the transfer wait list, and

0:17:54.956 --> 0:17:58.676
<v Speaker 2>we believe that this approach is justifiable with that goal

0:17:58.716 --> 0:18:01.476
<v Speaker 2>in mind. So every day we show up, we focus

0:18:01.556 --> 0:18:03.836
<v Speaker 2>on patients like mister Slayman. And so this is a

0:18:03.876 --> 0:18:06.436
<v Speaker 2>means to an end. This is a means to producing

0:18:06.556 --> 0:18:09.476
<v Speaker 2>organs that currently don't exist. It's to save paces who

0:18:09.476 --> 0:18:12.316
<v Speaker 2>are imminately dying, but they are. It's a very bleak

0:18:12.356 --> 0:18:14.596
<v Speaker 2>outlook for some of these folks, right, And so we

0:18:14.716 --> 0:18:17.036
<v Speaker 2>view that the work that we're doing for engineering the

0:18:17.036 --> 0:18:20.596
<v Speaker 2>persa and genome and producing compatible organs all about, you know,

0:18:20.676 --> 0:18:23.756
<v Speaker 2>realizing that mission of helping these patients, and we believe

0:18:23.756 --> 0:18:28.196
<v Speaker 2>that that puts us on a very firm ethical route.

0:18:29.916 --> 0:18:32.476
<v Speaker 1>Still to come on the show, how pig hearts might

0:18:32.596 --> 0:18:46.596
<v Speaker 1>help human babies. How many pigs with this genetic sequence

0:18:46.636 --> 0:18:46.996
<v Speaker 1>are there?

0:18:47.036 --> 0:18:49.756
<v Speaker 2>You have about fifty or so animals that are at

0:18:49.796 --> 0:18:50.476
<v Speaker 2>different ages.

0:18:50.796 --> 0:18:53.636
<v Speaker 1>So, like, do you have a farm somewhere?

0:18:54.076 --> 0:18:56.676
<v Speaker 2>So we do. We have two farms we have and

0:18:56.796 --> 0:18:59.356
<v Speaker 2>they are both out in the Midwest. One is a

0:18:59.396 --> 0:19:01.556
<v Speaker 2>research more of a research farm. It's a two hundred

0:19:01.596 --> 0:19:05.036
<v Speaker 2>acre farm where we institute biosecurity. So one of the

0:19:05.116 --> 0:19:07.716
<v Speaker 2>keys here is to produce animals that are free of

0:19:07.836 --> 0:19:11.356
<v Speaker 2>pathogens that could put harm to either the organs post

0:19:11.356 --> 0:19:15.156
<v Speaker 2>transplant or the patient or the recipients. So that farm

0:19:15.196 --> 0:19:18.036
<v Speaker 2>produces relatively clean animals. But then we have what we

0:19:18.076 --> 0:19:22.676
<v Speaker 2>call a clinical grade or designated pathogen free facility where

0:19:22.716 --> 0:19:24.756
<v Speaker 2>the animals are growing inside what we call a barrier.

0:19:25.516 --> 0:19:28.676
<v Speaker 2>So there we control feed, water, everything that comes in

0:19:28.716 --> 0:19:31.556
<v Speaker 2>to try to keep pathogens out. So we're actively managing

0:19:31.876 --> 0:19:35.436
<v Speaker 2>the environment that those animals are raised in. And on

0:19:35.516 --> 0:19:39.516
<v Speaker 2>top of all of that, we're doing very robust path

0:19:39.676 --> 0:19:44.516
<v Speaker 2>consistent pathogen testing, so we're constantly monitoring all the animals

0:19:44.556 --> 0:19:46.956
<v Speaker 2>for any potential pathogens or disease.

0:19:47.276 --> 0:19:50.756
<v Speaker 1>Right, I mean presumably some kind of like jumping the

0:19:50.836 --> 0:19:53.876
<v Speaker 1>species barrier or transfer would be one of the like

0:19:54.916 --> 0:19:57.036
<v Speaker 1>nightmarishly bad outcomes, right.

0:19:57.116 --> 0:19:59.676
<v Speaker 2>Yes, I mean one of the reasons that we selected

0:20:00.236 --> 0:20:03.276
<v Speaker 2>pigs as the species is one we've co you know,

0:20:03.396 --> 0:20:06.196
<v Speaker 2>existed with these animals for thousands of years and we

0:20:06.276 --> 0:20:09.556
<v Speaker 2>haven't seen that you know, that particular that type of

0:20:09.596 --> 0:20:12.676
<v Speaker 2>disease transmission, and then we can edit, and then we

0:20:12.716 --> 0:20:15.596
<v Speaker 2>also know how to grow animals at scale. But yes,

0:20:15.636 --> 0:20:17.196
<v Speaker 2>we're always on the lookout and I think this is

0:20:17.236 --> 0:20:20.476
<v Speaker 2>part of surveillance that we'll do for the foreseeable future,

0:20:21.036 --> 0:20:23.716
<v Speaker 2>is on the lookout for things that we aren't paying

0:20:23.716 --> 0:20:24.756
<v Speaker 2>attention for. Right.

0:20:25.276 --> 0:20:27.716
<v Speaker 1>So let's talk about the first patient. Let's talk about

0:20:27.756 --> 0:20:30.556
<v Speaker 1>Richard slam and the first person ever to be walking

0:20:30.596 --> 0:20:34.956
<v Speaker 1>the earth with a pig kidney as far as we know, probably.

0:20:37.316 --> 0:20:37.916
<v Speaker 2>Why him?

0:20:38.076 --> 0:20:40.076
<v Speaker 1>What was it about his case that made him the

0:20:40.156 --> 0:20:40.796
<v Speaker 1>right patient?

0:20:40.956 --> 0:20:43.236
<v Speaker 2>Yeah, So it's a great question, and part of it

0:20:43.276 --> 0:20:45.836
<v Speaker 2>was inspired by the work that was done at the

0:20:45.916 --> 0:20:49.316
<v Speaker 2>University of Maryland in the first heart transplants, right, so

0:20:49.356 --> 0:20:52.356
<v Speaker 2>we refer to those as the Bennett and Fossett transplants.

0:20:51.836 --> 0:20:55.676
<v Speaker 1>The first pig heart pig heart, Yeah, which just happened.

0:20:55.676 --> 0:20:59.356
<v Speaker 1>That was like a different project, right, but it just

0:20:59.356 --> 0:21:01.436
<v Speaker 1>happened in the last year or so, right now, the.

0:21:01.476 --> 0:21:03.836
<v Speaker 2>Last two years two years, Yeah, absolutely. And there was

0:21:03.836 --> 0:21:05.996
<v Speaker 2>always this debate in the field of zeno is what

0:21:06.036 --> 0:21:09.556
<v Speaker 2>patients would constitute the right patient population to go into

0:21:09.716 --> 0:21:12.276
<v Speaker 2>And the team at Maryland really showed us that there's

0:21:12.316 --> 0:21:14.636
<v Speaker 2>a case for compassionate use. There's a case for patients

0:21:14.636 --> 0:21:17.076
<v Speaker 2>who have reached the end of the treatment options and

0:21:17.116 --> 0:21:20.036
<v Speaker 2>really they're facing imminent death and we have a technology

0:21:20.036 --> 0:21:23.476
<v Speaker 2>that could save their life, so shouldn't we try now. Unfortunately,

0:21:23.556 --> 0:21:27.356
<v Speaker 2>you know, those gentlemen passed away within forty or fifty

0:21:27.436 --> 0:21:31.316
<v Speaker 2>days post transplant. But it showed us that the regulatory

0:21:31.316 --> 0:21:34.556
<v Speaker 2>agencies were open to the discussion, and we just need

0:21:34.596 --> 0:21:37.156
<v Speaker 2>to define what is the right patient population in the

0:21:37.196 --> 0:21:39.836
<v Speaker 2>case of kidney and so we had a discussion with

0:21:39.876 --> 0:21:43.036
<v Speaker 2>the FDA back in twenty twenty two about what would

0:21:43.076 --> 0:21:45.676
<v Speaker 2>be the right patient population for a formal phase one

0:21:45.716 --> 0:21:49.916
<v Speaker 2>clinical study, and we'd come to agreement on patients over fifty,

0:21:50.436 --> 0:21:53.796
<v Speaker 2>patients on the transplant weightlist, and patients that had failed

0:21:53.836 --> 0:21:56.316
<v Speaker 2>a previous alo transplant, right, so they'd had a human

0:21:56.396 --> 0:21:58.996
<v Speaker 2>kidney before, and they had it for a certain duration

0:21:59.036 --> 0:22:01.516
<v Speaker 2>of time and eventually that kidney fails and you find

0:22:01.516 --> 0:22:04.436
<v Speaker 2>yourself back on the transplant weightlist. And why that patient

0:22:04.476 --> 0:22:07.916
<v Speaker 2>population made sense is because those patients have a very

0:22:07.956 --> 0:22:12.036
<v Speaker 2>low likelihood if you're over fifty with that profile of

0:22:12.076 --> 0:22:15.036
<v Speaker 2>getting a second kidney. Now, in the case of mister Slamon,

0:22:15.036 --> 0:22:18.636
<v Speaker 2>are patients like him. He was also losing access to dialysis,

0:22:19.596 --> 0:22:24.396
<v Speaker 2>so he had a kidney transplant in twenty eighteen. He

0:22:24.436 --> 0:22:27.316
<v Speaker 2>had been on dialysis for seven years, got a kidney transplant,

0:22:27.596 --> 0:22:30.236
<v Speaker 2>the kidney function for five years, and then he lost

0:22:30.276 --> 0:22:34.236
<v Speaker 2>the kidney stop functioning. In twenty twenty three, Okay, he

0:22:34.276 --> 0:22:37.236
<v Speaker 2>found himself back on dialysis, but he was having trouble

0:22:37.276 --> 0:22:40.396
<v Speaker 2>with vascular access, so he had to go through multiple

0:22:40.396 --> 0:22:43.756
<v Speaker 2>surgeries to create access so he could go on dialysis.

0:22:43.956 --> 0:22:46.916
<v Speaker 1>And just to be clear, dialysis is when your kidneys

0:22:46.916 --> 0:22:48.596
<v Speaker 1>don't work. There is a machine and they hook you

0:22:48.676 --> 0:22:50.476
<v Speaker 1>up to the machine and it cleans your blood. It

0:22:50.516 --> 0:22:51.276
<v Speaker 1>does the work of the kids.

0:22:51.356 --> 0:22:53.316
<v Speaker 2>Yeah. Usually, you know, the typical schedule would be three

0:22:53.316 --> 0:22:54.876
<v Speaker 2>times a week, four hours each time.

0:22:54.956 --> 0:22:58.196
<v Speaker 1>Okay, And so Richard Slaman, you were saying dialysis just

0:22:58.596 --> 0:23:00.116
<v Speaker 1>wasn't working for him anymore.

0:23:00.156 --> 0:23:02.276
<v Speaker 2>In some patchion it was just very hard to do.

0:23:02.556 --> 0:23:04.316
<v Speaker 2>It was working, but he would have to have these

0:23:04.396 --> 0:23:08.556
<v Speaker 2>vascular access surgery so his blood vessels would acclude and

0:23:08.636 --> 0:23:10.796
<v Speaker 2>prevent the ability to do dialysis. So we'd have to

0:23:10.796 --> 0:23:13.956
<v Speaker 2>go through a relatively painful procedure to allow him to

0:23:13.956 --> 0:23:16.516
<v Speaker 2>get dialysis. And I think, you know, he was and

0:23:16.636 --> 0:23:20.396
<v Speaker 2>I think his neuprologist, when Williams put it really well,

0:23:20.396 --> 0:23:23.396
<v Speaker 2>he was kind of losing faith, losing hope, like, huh,

0:23:23.556 --> 0:23:25.716
<v Speaker 2>is this my life? Is this my future? Like, I'm

0:23:25.716 --> 0:23:28.236
<v Speaker 2>just going to have to keep doing this and I

0:23:28.276 --> 0:23:30.476
<v Speaker 2>have no chance of getting a transplant because he had

0:23:30.516 --> 0:23:32.836
<v Speaker 2>had a transplant for five years, so he knew what

0:23:32.916 --> 0:23:36.316
<v Speaker 2>that was and now he finds himself on dallasis. So,

0:23:36.316 --> 0:23:39.956
<v Speaker 2>so we knew at some point mister Sliman would lose

0:23:39.956 --> 0:23:42.716
<v Speaker 2>access to dialysis and without a transplant, he would he

0:23:42.716 --> 0:23:45.596
<v Speaker 2>would go to hospice. And so he was a patient

0:23:45.636 --> 0:23:49.596
<v Speaker 2>that we felt was a good candidate for trying. And

0:23:49.676 --> 0:23:52.956
<v Speaker 2>so the team at Mass General approached mister Slaman with

0:23:52.996 --> 0:23:55.876
<v Speaker 2>this idea of he could participate and be the first

0:23:55.876 --> 0:23:58.396
<v Speaker 2>patient to try this, and this is what we knew,

0:23:58.716 --> 0:24:01.116
<v Speaker 2>and these were the risks, and I think that's part

0:24:01.156 --> 0:24:04.076
<v Speaker 2>of one of the biggest challenges, kind of articulating what

0:24:04.116 --> 0:24:06.516
<v Speaker 2>we know and then articulately what we don't know and

0:24:06.556 --> 0:24:10.076
<v Speaker 2>how this could go. But much to mister slam his credit, right,

0:24:10.316 --> 0:24:12.036
<v Speaker 2>he was the one that raised his hand and said

0:24:12.036 --> 0:24:14.396
<v Speaker 2>he would go first. And then we took it to

0:24:14.396 --> 0:24:16.716
<v Speaker 2>the FDA and we laid out the case to the

0:24:16.756 --> 0:24:20.356
<v Speaker 2>FDA that you know mister Slamon's story and kind of

0:24:20.356 --> 0:24:22.716
<v Speaker 2>where he found himself in his treatment. What we had

0:24:22.756 --> 0:24:25.676
<v Speaker 2>been doing are non human primate data, all the data

0:24:25.716 --> 0:24:29.076
<v Speaker 2>on the characterization of our donors. And after a few

0:24:29.116 --> 0:24:32.916
<v Speaker 2>weeks of discussion, the FDA said, we agree and you

0:24:32.956 --> 0:24:34.436
<v Speaker 2>guys can try.

0:24:35.356 --> 0:24:39.716
<v Speaker 1>So what is the path for you for your fore genesis?

0:24:39.756 --> 0:24:42.876
<v Speaker 2>From here, we believe that there's the opportunity to treat

0:24:42.916 --> 0:24:46.516
<v Speaker 2>more patients like mister Slimon. He's not unfortunately, he's not

0:24:46.716 --> 0:24:48.596
<v Speaker 2>unique in this space, and there are other patients that

0:24:48.636 --> 0:24:51.996
<v Speaker 2>are suffering very similar fate with continued success. Our intention

0:24:52.156 --> 0:24:56.076
<v Speaker 2>is to do more of these expanded access requests and

0:24:56.116 --> 0:25:00.756
<v Speaker 2>transplants while we prepare for a formal trial, right so

0:25:01.156 --> 0:25:04.116
<v Speaker 2>in patients that may be facing less risk than patients

0:25:04.156 --> 0:25:08.196
<v Speaker 2>like mister Slamon, patients earlier in their dialysis journey, earlier

0:25:08.236 --> 0:25:12.436
<v Speaker 2>in their their kidney failure progression. But that will come,

0:25:12.636 --> 0:25:14.596
<v Speaker 2>you know. Our intention is to file something like that

0:25:14.636 --> 0:25:18.076
<v Speaker 2>at the end of twenty twenty five. Beyond that, you know,

0:25:18.116 --> 0:25:21.396
<v Speaker 2>we are also exploring patients that are suffering from liver

0:25:21.436 --> 0:25:25.556
<v Speaker 2>failure as well as heart failure. This past December, we

0:25:25.596 --> 0:25:30.156
<v Speaker 2>did the longest liver perfusions on liver perfusion in a

0:25:30.196 --> 0:25:34.556
<v Speaker 2>decedent patient. Ever, we did three days of continuous perfusion.

0:25:35.036 --> 0:25:36.916
<v Speaker 2>The idea there is you take a patient who may

0:25:36.916 --> 0:25:40.916
<v Speaker 2>be suffering from liver failure and perfuse them through a

0:25:40.956 --> 0:25:44.436
<v Speaker 2>pig liver to allow their own liver to recover again.

0:25:44.476 --> 0:25:48.116
<v Speaker 2>This was something that was demonstrated in the nineties to work.

0:25:48.156 --> 0:25:51.636
<v Speaker 2>So they took fourteen patients with acute liver failure perfused

0:25:51.636 --> 0:25:55.676
<v Speaker 2>them through pig livers. All fourteen patients improved. Seven patients

0:25:55.676 --> 0:25:57.516
<v Speaker 2>were successfully bridged to transplant.

0:25:58.196 --> 0:26:00.516
<v Speaker 1>So just to unpack that for a sec the pig

0:26:00.516 --> 0:26:02.076
<v Speaker 1>liver is kind of like when people get put on

0:26:02.116 --> 0:26:05.236
<v Speaker 1>those like external artificial hearts or something like the outside

0:26:05.276 --> 0:26:06.636
<v Speaker 1>the body, and it's like or.

0:26:06.596 --> 0:26:10.396
<v Speaker 2>What you know when think about kidney disease is akin

0:26:10.436 --> 0:26:13.436
<v Speaker 2>to dialsis right? You hooked up to a machine. In

0:26:13.476 --> 0:26:15.116
<v Speaker 2>this case, in the machine is a big.

0:26:14.916 --> 0:26:16.756
<v Speaker 1>Liver, and like, is it in a box?

0:26:17.036 --> 0:26:21.116
<v Speaker 2>Like yeah, yeah, So it's in a plastic container on

0:26:21.196 --> 0:26:22.156
<v Speaker 2>a perfusion device.

0:26:22.316 --> 0:26:25.036
<v Speaker 1>So the pig's liver is doing the work of the

0:26:25.076 --> 0:26:28.756
<v Speaker 1>liver for the patient while the patient is waiting for

0:26:28.876 --> 0:26:31.996
<v Speaker 1>a human donor exactly. Like, let me ask the dumb question,

0:26:32.276 --> 0:26:34.836
<v Speaker 1>why not just put the pigs liver in the person.

0:26:35.556 --> 0:26:39.716
<v Speaker 2>Because the incompatibilities between a pig liver and the person

0:26:39.716 --> 0:26:43.476
<v Speaker 2>are still too great. OK, So we could I think

0:26:43.476 --> 0:26:45.876
<v Speaker 2>we're only going to get a week or two before

0:26:45.916 --> 0:26:46.836
<v Speaker 2>that gets rejected.

0:26:47.316 --> 0:26:50.476
<v Speaker 1>And so similarly, does the perfusion just last for a

0:26:50.476 --> 0:26:52.756
<v Speaker 1>week or two it's just like an emergency bridge.

0:26:52.916 --> 0:26:55.356
<v Speaker 2>Yeah, so it's a great question, and we started out

0:26:55.396 --> 0:26:57.636
<v Speaker 2>with a goal of greater than twenty four hours of perfusion.

0:26:58.116 --> 0:27:00.716
<v Speaker 2>The pen study went for three days. Looking at the

0:27:00.756 --> 0:27:02.436
<v Speaker 2>histology at the end of the study, we believe it

0:27:02.436 --> 0:27:05.076
<v Speaker 2>can go for about a week. So we're continuing to

0:27:05.076 --> 0:27:05.836
<v Speaker 2>push the duration.

0:27:06.036 --> 0:27:08.996
<v Speaker 1>So that's like a that feels like much more of

0:27:08.996 --> 0:27:11.396
<v Speaker 1>a kind of edge case than the kidney case.

0:27:11.876 --> 0:27:13.796
<v Speaker 2>Well, this is the thing. We think there's actually much

0:27:13.836 --> 0:27:17.036
<v Speaker 2>greater unmet need and liver failure than there even is

0:27:17.036 --> 0:27:20.516
<v Speaker 2>in kidney failure because these patients, because there is no

0:27:20.796 --> 0:27:24.236
<v Speaker 2>equivalent of dialysis, they either recover on their own, which

0:27:24.276 --> 0:27:27.076
<v Speaker 2>is a little bit of like ICU time and hope,

0:27:27.356 --> 0:27:29.916
<v Speaker 2>or they get transplanted. So we're hoping that we can

0:27:29.956 --> 0:27:33.516
<v Speaker 2>provide liver support through a poresigne liver, we can bridge

0:27:33.556 --> 0:27:35.276
<v Speaker 2>more patients to recovery.

0:27:34.876 --> 0:27:38.356
<v Speaker 1>Okay, and then you're and then hearts.

0:27:38.476 --> 0:27:40.996
<v Speaker 2>Yeah. So the third setting, again is inspired by the

0:27:40.996 --> 0:27:44.676
<v Speaker 2>work done at Maryland, but instead of looking at adult

0:27:44.716 --> 0:27:47.916
<v Speaker 2>patients where the heart has to and heart has to

0:27:47.956 --> 0:27:51.756
<v Speaker 2>function continuously or the patient passes away, we're focused in

0:27:51.756 --> 0:27:55.236
<v Speaker 2>the pediatric population. So children who need a heart transplant

0:27:55.316 --> 0:27:57.636
<v Speaker 2>currently have poor standard of care to bridge them to

0:27:57.716 --> 0:27:58.596
<v Speaker 2>human heart transplant.

0:27:58.676 --> 0:28:02.076
<v Speaker 1>And so this is like typically like babies born with

0:28:02.196 --> 0:28:04.156
<v Speaker 1>genetic anomalies.

0:28:03.596 --> 0:28:06.516
<v Speaker 2>Yeah, typically children under two is kind of where the

0:28:06.516 --> 0:28:09.716
<v Speaker 2>focus is and the current support of care. About fifty

0:28:09.716 --> 0:28:13.276
<v Speaker 2>percent of these children die waiting for a human heart transplant.

0:28:14.476 --> 0:28:16.556
<v Speaker 1>That is a brutal one. Is a brutal That would

0:28:17.036 --> 0:28:18.996
<v Speaker 1>be a good one too, Yeah, that would be a

0:28:18.996 --> 0:28:19.916
<v Speaker 1>good one to tve.

0:28:20.156 --> 0:28:22.356
<v Speaker 2>And so the idea is if we can simply create

0:28:22.396 --> 0:28:26.076
<v Speaker 2>one hundred to two hundred day bridge using a Poresigne heart,

0:28:26.076 --> 0:28:28.076
<v Speaker 2>then at the end of that or sometime in the middle,

0:28:28.196 --> 0:28:30.916
<v Speaker 2>when the human heart became available, the child would simply

0:28:30.956 --> 0:28:33.836
<v Speaker 2>get the human heart. So we call that a bridging strategy.

0:28:34.356 --> 0:28:37.076
<v Speaker 1>And so in that instance, is it a transplant or

0:28:37.156 --> 0:28:38.876
<v Speaker 1>is it external It's a transplant.

0:28:38.996 --> 0:28:42.196
<v Speaker 2>Yeah, So the intention is to do the por signed

0:28:42.196 --> 0:28:45.036
<v Speaker 2>heart transplant allow the patient to go home. They can

0:28:45.076 --> 0:28:47.156
<v Speaker 2>wait at home right now, they would have to wait

0:28:47.196 --> 0:28:49.236
<v Speaker 2>in the hospital, but they could wait at home until

0:28:49.236 --> 0:28:50.556
<v Speaker 2>the human heart becomes available.

0:28:51.076 --> 0:28:56.436
<v Speaker 1>Okay, So so those are two other organs. When do

0:28:56.476 --> 0:28:57.516
<v Speaker 1>you think you're going to do those?

0:28:58.076 --> 0:29:00.116
<v Speaker 2>So the intention, the intention is to do all that

0:29:00.196 --> 0:29:02.276
<v Speaker 2>this year, right, So, we believe we have the not

0:29:02.316 --> 0:29:04.996
<v Speaker 2>what we call non clinical data or the primate data

0:29:05.716 --> 0:29:07.836
<v Speaker 2>to support moving into the clinic. And I do think

0:29:08.156 --> 0:29:10.916
<v Speaker 2>mister the success so far with mister Slaman's transplant is

0:29:10.956 --> 0:29:13.716
<v Speaker 2>helpful because the emune of suppression that we plan to

0:29:13.916 --> 0:29:17.276
<v Speaker 2>use in the pediatric heart setting is very similar to

0:29:17.316 --> 0:29:20.356
<v Speaker 2>what we're using in mister Slaman's transplant. So we do

0:29:20.436 --> 0:29:24.716
<v Speaker 2>think that continued success in the kidney transplant will help

0:29:24.716 --> 0:29:26.676
<v Speaker 2>inform what we're going to be doing at heart.

0:29:27.596 --> 0:29:31.996
<v Speaker 1>And is it the same set of genetic changes?

0:29:32.476 --> 0:29:35.156
<v Speaker 2>Yeah, so it's the same genetics of the donor. So

0:29:35.196 --> 0:29:37.436
<v Speaker 2>the current plan is to use the same donor for

0:29:37.516 --> 0:29:41.356
<v Speaker 2>both kidney, hearts and livers.

0:29:41.396 --> 0:29:46.876
<v Speaker 1>And how does how does the immune response to a

0:29:46.916 --> 0:29:50.956
<v Speaker 1>pig organ compare to the immune response to an organ

0:29:50.996 --> 0:29:52.116
<v Speaker 1>from another human?

0:29:52.636 --> 0:29:54.516
<v Speaker 2>Yeah, it's definitely more robust.

0:29:55.036 --> 0:29:57.716
<v Speaker 1>More robust meaning worse in this concept, it's.

0:29:57.556 --> 0:29:59.916
<v Speaker 2>Probably going to require you know, we already are using

0:29:59.956 --> 0:30:01.556
<v Speaker 2>more evenie suppression. Yeah.

0:30:01.596 --> 0:30:06.516
<v Speaker 1>And is there some medium to long term future where

0:30:06.556 --> 0:30:12.516
<v Speaker 1>you do more gene editing in order to make that

0:30:12.556 --> 0:30:15.316
<v Speaker 1>piece of it easier, where you make the pig kidney

0:30:15.356 --> 0:30:16.436
<v Speaker 1>more like a human kidney.

0:30:16.516 --> 0:30:18.556
<v Speaker 2>Yeah. Absolutely. The long term vision here is to produce

0:30:18.676 --> 0:30:21.396
<v Speaker 2>organs that don't require immuno suppression, party.

0:30:21.276 --> 0:30:22.396
<v Speaker 1>That don't require it at.

0:30:22.316 --> 0:30:24.596
<v Speaker 2>All at all. I mean, that's the ultimate that's the vision.

0:30:24.636 --> 0:30:26.556
<v Speaker 1>I mean, if you could do that. Just to be clear,

0:30:27.116 --> 0:30:30.676
<v Speaker 1>like that vision is a pig kidney is better than

0:30:30.716 --> 0:30:32.196
<v Speaker 1>a kidney from another human.

0:30:32.036 --> 0:30:35.556
<v Speaker 2>Right, I mean it sounds like you've been talking to George. Wow.

0:30:36.276 --> 0:30:38.636
<v Speaker 1>I appreciate that you were skeptical. You were supposed to

0:30:38.636 --> 0:30:40.956
<v Speaker 1>be high picking up and I'm supposed to be skeptical. No.

0:30:41.036 --> 0:30:43.596
<v Speaker 1>But if you say, like, is that even plausible? I

0:30:43.596 --> 0:30:45.396
<v Speaker 1>appreciate that you're skeptical of it. That's good.

0:30:45.476 --> 0:30:47.556
<v Speaker 2>Yeah, do it might work for me. I think one

0:30:47.596 --> 0:30:49.276
<v Speaker 2>of the things that transplant World has taught us over

0:30:49.276 --> 0:30:51.636
<v Speaker 2>the past fifty years is things that we thought were

0:30:51.676 --> 0:30:54.836
<v Speaker 2>impossible are actually now routine, right, So I think it's

0:30:54.836 --> 0:30:58.156
<v Speaker 2>a matter of time, effort, and work. I think we

0:30:58.196 --> 0:31:01.356
<v Speaker 2>can get there, right. I think this initial transplant into

0:31:01.596 --> 0:31:04.556
<v Speaker 2>patients is a really important step because for us to

0:31:04.716 --> 0:31:06.396
<v Speaker 2>be informed about what we need to do from an

0:31:06.436 --> 0:31:09.596
<v Speaker 2>engineering perspective, it is very helpful to have data from

0:31:09.676 --> 0:31:12.996
<v Speaker 2>humans to feedback into that loop, so we can do

0:31:13.356 --> 0:31:16.396
<v Speaker 2>lots of things from an engineering perspective. The question is

0:31:16.396 --> 0:31:18.516
<v Speaker 2>what to do next, and I think the results that

0:31:18.796 --> 0:31:21.916
<v Speaker 2>will achieve with mister Slayman and patients like him will

0:31:21.956 --> 0:31:24.916
<v Speaker 2>help inform what else we need to do to really

0:31:24.916 --> 0:31:27.916
<v Speaker 2>realize this big vision, which is organs that don't require suppression.

0:31:28.356 --> 0:31:33.076
<v Speaker 1>Organs that don't require suppression, is wildly ambitious, right do you?

0:31:33.156 --> 0:31:37.076
<v Speaker 1>I mean it seems like, not knowing basically anything about it,

0:31:37.076 --> 0:31:42.076
<v Speaker 1>it would be a kind of incremental, maybe even as symptotic, like, ah,

0:31:42.116 --> 0:31:44.316
<v Speaker 1>this will get us to less, This will get us

0:31:44.316 --> 0:31:47.436
<v Speaker 1>to less as opposed to some binary breakthrough. Does that

0:31:47.436 --> 0:31:47.956
<v Speaker 1>seem right?

0:31:48.156 --> 0:31:50.996
<v Speaker 2>Yeah? I think it's incremental. But what we're starting to

0:31:51.036 --> 0:31:56.756
<v Speaker 2>see is kind of multiplex editing in a way that

0:31:56.796 --> 0:31:59.196
<v Speaker 2>we couldn't even before Christper, we couldn't conceive of making

0:31:59.196 --> 0:32:02.076
<v Speaker 2>fifty nine edits for GENO. Okay, now we're conceiving of

0:32:02.796 --> 0:32:05.036
<v Speaker 2>how would you make a thousand edits to geno? What

0:32:05.076 --> 0:32:07.196
<v Speaker 2>does that actually look like? And I think that's what's

0:32:07.236 --> 0:32:08.116
<v Speaker 2>going to be required. Huh.

0:32:08.436 --> 0:32:11.036
<v Speaker 1>I mean, do you get weird like structural like three

0:32:11.156 --> 0:32:13.876
<v Speaker 1>D structural problems once you start doing that, like is

0:32:13.916 --> 0:32:15.836
<v Speaker 1>it even gonna yes work?

0:32:16.076 --> 0:32:18.156
<v Speaker 2>So there's definitely a lot to solve, right, So how

0:32:18.196 --> 0:32:19.796
<v Speaker 2>do you make you know, how do you make that

0:32:19.876 --> 0:32:23.436
<v Speaker 2>many changes without totally destroying the geno? We thought that

0:32:23.516 --> 0:32:27.196
<v Speaker 2>originally with Crisper and the first retroviolent activation, they thought

0:32:27.196 --> 0:32:28.676
<v Speaker 2>you would never be able to make that many at it.

0:32:28.716 --> 0:32:30.756
<v Speaker 2>So we did that. We just have to figure out

0:32:30.796 --> 0:32:32.836
<v Speaker 2>how to do it. And you know, we don't know

0:32:32.876 --> 0:32:35.236
<v Speaker 2>how to do it right now, but I do think

0:32:35.236 --> 0:32:36.236
<v Speaker 2>we'll figure out how to do it.

0:32:38.716 --> 0:32:54.756
<v Speaker 1>We'll be back in a minute with the lightning. Let's

0:32:54.756 --> 0:32:56.756
<v Speaker 1>finish with a lightning ground. I won't take much more

0:32:56.756 --> 0:32:57.156
<v Speaker 1>of your time.

0:32:57.436 --> 0:33:00.116
<v Speaker 2>Okay, Okay, what's one.

0:32:59.956 --> 0:33:03.596
<v Speaker 1>Thing that that we don't understand about the human body

0:33:03.636 --> 0:33:11.956
<v Speaker 1>that you wish we understood?

0:33:12.876 --> 0:33:15.796
<v Speaker 2>I think, coming from the neuroscience world, I think we

0:33:15.836 --> 0:33:22.116
<v Speaker 2>have a really poor understanding of mental health and what

0:33:22.156 --> 0:33:25.356
<v Speaker 2>to do about depression, and because I think those are

0:33:25.396 --> 0:33:30.076
<v Speaker 2>just paralyzing diseases that we are a long way from

0:33:30.196 --> 0:33:33.716
<v Speaker 2>really understanding why they exist and actually how to effectively

0:33:33.756 --> 0:33:36.156
<v Speaker 2>treat them. So if you could generalize that as brain,

0:33:36.236 --> 0:33:40.476
<v Speaker 2>we still don't really understand in the way we need to,

0:33:40.636 --> 0:33:42.436
<v Speaker 2>you know, how the brain actually works and what we

0:33:42.476 --> 0:33:44.876
<v Speaker 2>can do to improve diseases of the brain.

0:33:46.596 --> 0:33:50.156
<v Speaker 1>Well, I know you worked in pharmaceuticals for decades, right,

0:33:50.196 --> 0:33:53.676
<v Speaker 1>I don't point on it, Yeah, and so you know

0:33:53.796 --> 0:33:57.236
<v Speaker 1>it's a famously hard industry. Most drugs fail, right, I'm

0:33:57.276 --> 0:34:01.356
<v Speaker 1>curious if you have any any tips for dealing with failure.

0:34:02.676 --> 0:34:04.876
<v Speaker 2>I think you go in with the best hypothesis, you

0:34:04.956 --> 0:34:07.596
<v Speaker 2>run the most efficient studies you can, and then you

0:34:07.636 --> 0:34:10.956
<v Speaker 2>pick yourself up and go again, because I think you

0:34:10.996 --> 0:34:13.556
<v Speaker 2>can't let failure bring you down, right, And we know

0:34:13.636 --> 0:34:15.916
<v Speaker 2>we're going to fail, and often we learned a tremendous

0:34:15.956 --> 0:34:18.356
<v Speaker 2>amount from those failures and we just have to build

0:34:18.356 --> 0:34:20.156
<v Speaker 2>on them. The worst thing you can do is stop.

0:34:20.676 --> 0:34:22.316
<v Speaker 2>I think you have to always keep going.

0:34:23.276 --> 0:34:25.316
<v Speaker 1>So if you look back over the thirty years that

0:34:25.356 --> 0:34:27.356
<v Speaker 1>you worked in the drug industry, I'm curious, like, if

0:34:27.356 --> 0:34:29.156
<v Speaker 1>you think about when you were getting into the field.

0:34:30.516 --> 0:34:34.036
<v Speaker 1>What is something that has happened since then, like a breakthrough,

0:34:34.076 --> 0:34:37.356
<v Speaker 1>a change that you wouldn't have expected that's surprising to you.

0:34:41.836 --> 0:34:45.316
<v Speaker 2>I think this whole field of genetic medicines, you know

0:34:45.356 --> 0:34:47.996
<v Speaker 2>the fact that we're now producing potential cures for sickle cell,

0:34:48.636 --> 0:34:51.796
<v Speaker 2>cures for beta thalsemia. I think those were all visions

0:34:52.236 --> 0:34:54.756
<v Speaker 2>that we had, you know, fifty sixty one hundred years ago,

0:34:55.036 --> 0:34:58.356
<v Speaker 2>like could we actually cure diseases that we're now literally

0:34:58.356 --> 0:35:00.636
<v Speaker 2>on the shelf have cures for. And I think that

0:35:00.916 --> 0:35:02.836
<v Speaker 2>no one ever thought we would get there, and here

0:35:02.876 --> 0:35:03.356
<v Speaker 2>we are.

0:35:03.236 --> 0:35:07.796
<v Speaker 1>So conversely, so that's the happy surprise. Is there something

0:35:07.836 --> 0:35:11.116
<v Speaker 1>when you got into the field that you fought like,

0:35:11.236 --> 0:35:14.516
<v Speaker 1>surely we'll figure this out, Surely this will be solved

0:35:14.556 --> 0:35:15.516
<v Speaker 1>that we haven't figured out.

0:35:15.676 --> 0:35:19.276
<v Speaker 2>I mean, our inability to really effectively fight viral infection is,

0:35:19.836 --> 0:35:23.356
<v Speaker 2>you know, our infectious disease broadly. We really haven't evolved

0:35:23.996 --> 0:35:27.716
<v Speaker 2>our armamentarium against infectious disease very much. I think there

0:35:27.836 --> 0:35:31.476
<v Speaker 2>we've way under invested and focused on infectious disease. I

0:35:31.476 --> 0:35:35.436
<v Speaker 2>don't think the current way we fund drug development doesn't

0:35:35.476 --> 0:35:38.636
<v Speaker 2>support active work there. I think it's the one. It's

0:35:38.636 --> 0:35:40.316
<v Speaker 2>a blind spot for us, and I think we saw it,

0:35:40.596 --> 0:35:41.396
<v Speaker 2>you know, during COVID.

0:35:41.476 --> 0:35:43.196
<v Speaker 1>Yeah, right, so.

0:35:45.036 --> 0:35:46.956
<v Speaker 2>And it's still a blind spot. What's really sad is

0:35:46.956 --> 0:35:49.196
<v Speaker 2>I don't think COVID. Actually, I don't think we've done

0:35:49.236 --> 0:35:50.956
<v Speaker 2>much different than we were.

0:35:50.796 --> 0:35:56.996
<v Speaker 3>Doing that that that hurts, but I think it's true.

0:35:58.236 --> 0:36:02.836
<v Speaker 1>Mike Curtis is the CEO of E Genesis. Today's show

0:36:02.996 --> 0:36:06.236
<v Speaker 1>was produced by Gabriel Hunter Chang. It was edited by

0:36:06.276 --> 0:36:10.356
<v Speaker 1>Lydia jene Kott and engineered by Sarah. You can email

0:36:10.436 --> 0:36:14.356
<v Speaker 1>us at problem at Pushkin dot FM. I'm Jacob Goldstein

0:36:14.396 --> 0:36:16.636
<v Speaker 1>and we'll be back next week with another episode of

0:36:16.636 --> 0:36:17.396
<v Speaker 1>What's Your Problem.